CLAIMS

1. Use of an effective dose of udenafil, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a patient with single ventricle heart disease, who has had a Fontan procedure, for improving the patient's exercise capacity and cardiac output, whose exercise capacity and cardiac output are adversely affected due to a decline in the patient's heart function after the Fontan procedure, in which the medicament is formulated to be administered in a total daily dose of udenafil or a pharmaceutically acceptable salt thereof from about 125 mg to about 175 mg, in which the patient is in need of treatment to improve the patient's exercise capacity and cardiac output, and in which the patient is at least about 12 years of age or older'.

2. Use according to Claim 1, in which the patient has Fontan physiology and is an adolescent who is from about 12 years of age to about 18 years of age.

3. Use according to Claim 1, in which the udenafil or the pharmaceutically acceptable salt thereof is in a solid oral dosage form.

4. Use according to Claim 3, in which the solid oral dosage form is a tablet.

5. Use according to Claim 1, in which the udenafil or the pharmaceutically acceptable salt thereof is a solid or semi-solid oral dosage form selected from the group consisting of: a tablet, a capsule, a gel, a liquid, a liquid dispersion, a pill, a powder and a suspension.

6. Use of udenafil or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a patient with single ventricle heart defect, who has had Fontan procedure, for improving the patient's exercise capacity and cardiac output, whose exercise capacity and cardiac output are adversely affected due to a decline in the patient's heart function after the Fontan procedure, in which the medicament is formulated to be administered in a dose of 87.5 mg, in which the patient is in need of treatment to improve the patient's exercise capacity and cardiac output, in which the medicament is administered at least once or twice daily, and in which the patient is at least about 12 years of age or older.

7. Use according to Claim 6, in which the patient has Fontan physiology and is an adolescent patient of about 12 to about 18 years of age.

8. Use according to Claim 6, in which the udenafil or the pharmaceutically acceptable salt thereof is in a solid oral dosage form.

9. Use according to Claim 8, in which the solid oral dosage form is a tablet.

10. Use according to Claim 6, in which the udenafil or the pharmaceutically acceptable salt thereof is a solid or semi-solid oral dosage form selected from the group consisting of: a tablet, a capsule, a gel, q liquid, a liquid dispersion, a pill, a powder and a suspension.

11. Use according to any preceding claim, in which the pharmaceutically acceptable salt of udenafil is an acid addition salt.

12. Use according to any preceding claim, in which the patient's improvement in exercise capacity is determined at the human patient's ventilatory anaerobic threshold (VAT).

13. Use according to any preceding claim, in which the patient's improvement in exercise capacity is determined by the human patient's oxygen consumption at the human patient's maximal effort or max VO_2.

14. Use according to any preceding claim, in which the exercise capacity is aerobic exercise capacity.

15. Use according to any preceding claim, in which the use improves the patient's ventricular performance.

16. Use according to any preceding claim, in which the use improves patient's myocardial performance.

17. Use according to any preceding claim, in which the use in the patient results in a pharmacokinetic profile selected from a group of pharmacokinetic profiles consisting of a C_{max} between 300 and 700 ng/ml, a T_{max} between 1 and 1.6 hr, an AUC_{τ} of between 2550 and 4150 ng•hr/ml, and/or an AUC_{0-24} between 5110 and 8290 ng•hr/ml.

18. Use according to any of Claims 1 to 16, in which the use in the patient results in a C_{max} of 500 ng/ml or more.

19. Use according to any of Claims 1 to 16, in which the use in the patient results in a T_{max} of 1.3 hr or greater.

20. Use according to any of Claims 1 to 16, in which the use in the patient results in an AUC_{τ} of 3350 ng•hr/ml or more.

21. Use according to any of Claims 1 to 16, in which the use in the patient results in an AUC_{0-24} of 6700 or more ng•hr/ml.

22. Use according to Claim 6, in which the patient has renal impairment and the medicament is administered once daily.

23. Use according to any preceding claim, in which the patient is a paediatric patient.

24. Use according to Claim 22, in which the deleterious effects of the Fontan physiology are minimized.

25. Use according to any of Claims 1 to 23, in which the decline of clinically relevant measurements indicative of the patient's health following the Fontan procedure is improved.